4.7 Review

Diazido platinum(iv) complexes for photoactivated anticancer chemotherapy

Journal

INORGANIC CHEMISTRY FRONTIERS
Volume 6, Issue 7, Pages 1623-1638

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/c9qi00288j

Keywords

-

Funding

  1. MRC [G0701062]
  2. EPSRC [EP/G006792, EP/F034210/1, EP/P030572/1]
  3. ERC [247450]
  4. University of Warwick
  5. Wellcome Trust [209173/Z/17/Z]
  6. EPSRC [EP/P030572/1, EP/F034210/1] Funding Source: UKRI
  7. MRC [G0701062] Funding Source: UKRI
  8. Wellcome Trust [209173/Z/17/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

Diazido Pt(iv) complexes with a general formula [Pt(N-3)(2)(L)(L ')(OR)(OR ')] are a new generation of anticancer prodrugs designed for use in photoactivated chemotherapy. The potencies of these complexes are affected by the cis/trans geometry configuration, the non-leaving ligand L/L ' and derivatisation of the axial ligand OR/OR '. Diazido Pt(iv) complexes exhibit high dark stability and promising photocytotoxicity circumventing cisplatin resistance. Upon irradiation, diazido Pt(iv) complexes release anticancer active Pt(ii) species, azidyl radicals and ROS, which interact with biomolecules and therefore affect the cellular components and pathways. The conjugation of diazido Pt(iv) complexes with anticancer drugs or cancer-targeting vectors is an effective strategy to optimise the design of these photoactive prodrugs. Diazido Pt(iv) complexes represent a series of promising anticancer prodrugs owing to their novel mechanism of action which differs from that of classical cisplatin and its analogues.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available